Zhang Xin, Zhao Ruixia, Qi Yao, Yan Xiong, Qi Gaoxiu, Peng Qiuju
Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao Central Medical Group, Qingdao, Shandong, China.
Qingdao Chest Hospital, Qingdao, Shandong, China.
Front Med (Lausanne). 2024 Oct 21;11:1455715. doi: 10.3389/fmed.2024.1455715. eCollection 2024.
Tuberculosis (TB) has been troubling humans for hundreds of years, is a highly infectious disease caused by (Mtb) infection, Mtb can infect almost all organs of the body and is one of the deadly infectious diseases in the world. At present, the first-line treatment regimen has a long treatment cycle and is prone to multiple drug resistance. Anti-tuberculosis drugs and latent tuberculosis infection (LTBI) resistance are increasing year by year, and new targets and new bioactive compounds are urgently needed to treat this disease. This review focuses on the latest reported anti-TB drug targets and related compounds in recent years, reviews the current TB drug regimen and major defects, outlines the key drug targets developed to date in Mtb, and the current situation of newly discovered anti-TB resistant forms of drugs. To provide a reference for the research and development of new anti-TB drugs and bring new treatment strategies for TB patients.
结核病困扰人类已有数百年之久，是由结核分枝杆菌（Mtb）感染引起的一种高度传染性疾病，Mtb可感染人体几乎所有器官，是世界上致命的传染病之一。目前，一线治疗方案治疗周期长，且容易产生多重耐药性。抗结核药物和潜伏性结核感染（LTBI）耐药性逐年增加，迫切需要新的靶点和新的生物活性化合物来治疗这种疾病。本综述聚焦于近年来最新报道的抗结核药物靶点及相关化合物，回顾了当前的结核病药物治疗方案及主要缺陷，概述了迄今为止在Mtb中开发的关键药物靶点，以及新发现的抗结核耐药形式药物的现状。旨在为新型抗结核药物的研发提供参考，为结核病患者带来新的治疗策略。
